Protection from hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble epoxide hydrolase

Rebecca L. Charles\textsuperscript{a}, Olena Rudyk\textsuperscript{b}, Oleksandra Prysyazhna\textsuperscript{a}, Alisa Kamynina\textsuperscript{a}, Jun Yang\textsuperscript{b,c}, Christophe Morisseau\textsuperscript{b,c}, Bruce D. Hammock\textsuperscript{b,c}, Bruce A. Freemand\textsuperscript{d}, and Philip Eaton\textsuperscript{a,1}

\textsuperscript{a}King’s College London, Cardiovascular Division, British Heart Foundation Centre of Excellence, The Rayne Institute, St. Thomas’ Hospital, London SE1 7EH, United Kingdom; \textsuperscript{b}Department of Entomology and Nematology, and \textsuperscript{c}University of California, Davis Comprehensive Cancer Center, University of California, Davis, CA 95616; and \textsuperscript{d}Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261

Edited by Louis J. Ignarro, University of California, Los Angeles School of Medicine, Beverly Hills, CA, and approved April 24, 2014 (received for review February 17, 2014)

Soluble epoxide hydrolase (sEH) is inhibited by electrophilic lipids by their addition to Cys521 proximal to its catalytic center. This inhibition prevents hydrolysis of the enzymes’ epoxyeicosatrienoic acid (EET) substrates, so they accumulate inducing vasodilation to lower blood pressure (BP). We generated a Cys521Ser sEH redox-dead knockin (KI) mouse model that was resistant to this mode of inhibition. The electrophilic lipid 10-nitro-octadec-9-enoic acid (NO\textsubscript{2}-OA) inhibited hydrolase activity and also lowered BP in an angiotensin II-induced hypertension model in wild-type (WT) but not KI mice. Furthermore, EET/dihydroxy-epoxyeicosatrienoic acid isomer ratios were elevated in plasma from WT but not KI mice following II-induced hypertension model in wild-type (WT) but not KI mice feeding low nitrate diet. When the electron-withdrawing nitro group is bonded to alkyl groups, this confers an electrophilic reactivity to fatty acids (17, 18). Thus, fatty acid nitroalkanes can modify proteins covalently via reversible Michael addition reactions that overall serves to link cellular metabolic and redox homeostasis with the posttranslational regulation of target protein function.

Nitro fatty acids, which have been detected endogenously in plasma and urine of humans, animal models, and plants (19–21), mediate salutary cardiovascular signaling actions (22). For example, they relax blood vessels, attenuate platelet activation, and reduce inflammation via cyclic guanosine monophosphate (cGMP)-independent mechanisms (23, 24). Of relevance, the Mediterranean diet is characterized by high consumption of unsaturated fatty acids, especially from olive oil and fish rich in oleic and linoleic acid, together with vegetables rich in nitrite and nitrate (25). The acidic and low-oxygen conditions in the stomach provide an environment for efficient nitrification of such unsaturated fatty acids by nitrite (26). NO\textsubscript{2}-OA normalizes blood pressure in an angiotensin (Ang) II-induced murine model of hypertension via undefined mechanisms (27). This was notable as pharmacological inhibitors of sEH also lower BP in murine hypertension, including salt- or Ang II-induced models (6, 7). As NO\textsubscript{2}-OA inhibits sEH, we hypothesized that this mechanism may account for BP lowering in the setting of hypertension. Furthermore, as the Mediterranean diet both contains nitro fatty acids and can elevate their endogenous generation, this mechanism may contribute to the endogenous formation of nitro fatty acids. These reactive lipids add to soluble epoxide hydrolase, inhibiting it to lower blood pressure. Mice genetically engineered to be resistant to this additive inhibition had high blood pressure basally and their hydrolase activity was fully resistant to inhibition by nitro fatty acid supplied directly or generated via the Mediterranean diet. Similarly nitro fatty acid lowered blood pressure and abrogated cardiac hypertrophy in a hypertension model in wild-type mice, but was ineffective in mutant mice. Thus, protection from hypertension afforded by the Mediterranean diet is mediated by nitro-fatty acid-dependent inhibition of soluble epoxide hydrolase.

Significance

The Mediterranean diet is characterized by consumption of unsaturated fats with vegetables rich in nitrite and nitrate, resulting in endogenous formation of nitro fatty acids. These reactive lipids add to soluble epoxide hydrolase, inhibiting it to lower blood pressure. Mice genetically engineered to be resistant to this additive inhibition had high blood pressure basally and their hydrolase activity was fully resistant to inhibition by nitro fatty acid supplied directly or generated via the Mediterranean diet. Similarly nitro fatty acid lowered blood pressure and abrogated cardiac hypertrophy in a hypertension model in wild-type mice, but was ineffective in mutant mice. Thus, protection from hypertension afforded by the Mediterranean diet is mediated by nitro-fatty acid-dependent inhibition of soluble epoxide hydrolase.
dietary-induced BP decreases that in turn will reduce the risk of adverse cardiovascular event (28).

Given the complexity of causally establishing whether nitro fatty acids lower BP by inhibiting sEH, especially in the setting of dietary-induced endogenous fatty acid nitration, we generated a Cys521Ser sEH knockin (KI) mouse. This “redox-inactive” sEH thiol mutant, rendered insensitive to adductive inhibition by lipid electrophiles in vitro, provided a novel model system for testing the impact of lipid nitroalkenes on sEH hydrolysis of vasoactive EET species and downstream physiological responses (1). The data reveal that nitro fatty acids, applied exogenously as a pharmacological agent or generated endogenously as part of the Mediterranean diet, inhibit sEH to elevate plasma EETs, which in turn lower BP.

Results

NO2-OA-Dependent Vasodilation Is Impaired in Cys521Ser KI Blood Vessels. NO2-OA caused a dose-dependent vasodilation in isolated WT and KI mesenteric blood vessels. However, vasodilation to NO2-OA was impaired in the KI, as indicated by a significant rightward shift in the response curve compared with the WT (Fig. 1A, P < 0.05). The half-maximal effective concentration (EC50) for NO2-OA was 113.9 ± 24.9 nM in WT compared with 354.5 ± 62.7 nM for KI vessels. This indicates the KI vessels are less sensitive to NO2-OA than WT and is consistent with the anticipated phenotype, given the Cys521Ser sEH mutant was engineered to be resistant to adductive inhibition by lipid electrophiles. WT mesenteric vessels were incubated with or without the soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and the dose-dependent relaxation responses to NO2-OA were compared. ODQ did not alter the vasodilation induced by NO2-OA alone (Fig. 1B).

NO2-OA-Dependent Inhibition of sEH Is Deficient in Cys521Ser KI in Vivo. NO2-OA or vehicle control was delivered systemically to WT or KI mice using osmotic minipumps. The hearts of mice were assessed for sEH activity, which was lower in KI than WT. This is consistent with previous observations that a Cys521Ser sEH mutant transplanted into cells was less active than WT hydrolase (1). NO2-OA significantly inhibited sEH activity in WT but not KI mice, consistent with the latter being deficient in the cysteine thiol target for lipid electrophile adduction (Fig. 1C).

NO2-OA Abrogates Ang II-Induced Hypertension in WT but Not KI Mice in Vivo. The mean arterial pressure (MAP) was ∼9 mmHg higher in KI mice compared with WT littermate controls (Fig. 2A and B), consistent with a role for Cys521 of sEH in transducing vasodilatory responses of lipid electrophiles. Ang II increased MAP in both genotypes (Fig. 2C and D), but this initial hypertensive response was potentiated by ∼5 mmHg in KI compared with WT. Thus, Ang II increased MAP by 15 mmHg in WT compared with 20 mmHg in KI (Fig. 2E and F). Administration of NO2-OA reduced MAP in Ang II hypertensive WT mice, but was wholly ineffective in lowering BP in littermate KIs (Fig. 2C–E and G).

Oxylipid Profile Analysis of Plasma Following Ang II and NO2-OA Treatment. Plasma was collected from WT and KI mice at baseline and at the end of the Ang II + NO2-OA treatment (as depicted in Fig. 2C and D) for oxylipid profile analysis. EETs, dihydroxyepoxyeicosatrienoic acids (DHETs) and hydroxy-eicosatetraenoic (HETEs) were measured by liquid chromatography tandem mass spectrometry. Basally, there was no difference in 8,9-, 11,12-, and 14,15-EET/DHET isomer ratios measured among WT compared with KI plasma. However, 15-HETE and 11-HETE were significantly decreased in KI compared with WT plasma. There was a similar tendency for plasma 8-HETE and 9-HETE to also be lower in KI than WT (Fig. 3A). Following the Ang II + NO2-OA treatment, the 8,9-, 11,12-, and 14,15-EET/DHET isomer ratios were significantly higher in plasma from WT mice compared with KI mice (∗P < 0.05). The 5,6 EET/DHET ratio also showed the same tendency but differences did not reach statistical significance (Fig. 3B).

NO2-OA Abrogates Ang II-Induced Hypertrophy in WT but Not Cys521Ser sEH KI. Consistent with Ang II inducing hypertension in WT as well as KI mice, the hearts from both genotypes became hypertrophic following this intervention (Fig. 3C). Ang II-induced hypertrophy in WT mice was abrogated by NO2-OA, whereas this was ineffective in the KI (Fig. 3C). Again, the failure of NO2-OA to combat Ang II-induced hypertrophy in KI mice was consistent with a failure to alleviate hypertension in this genotype (Fig. 2D).

NO2-OA Addition to WT but Not Cys522Ser KI sEH. A Western immunoblot-based assay that allows the stoichiometry of reversible
thiol modifications to be determined using an antibody to the protein of interest, in this case sEH, was undertaken. This procedure, known as the PEG-switch assay (29, 30), showed there was a basal level of reversible sEH modification in WT that was significantly increased following NO2-OA treatment (Fig. 4A, P < 0.05). In contrast, KI mice showed no such increase (Fig. 4A), a consequence of the lack of the Cys521 thiol target.

**Nitro Fatty Acids Are Formed from Dietary Components and Inhibit WT but Not KI sEH.** The hearts of mice gavaged with conjugated linoleic acid (CLA) and sodium nitrite were assayed for sEH activity. This dietary intervention, which mimics aspects of the Mediterranean diet, significantly inhibited sEH activity in WT mice but not in KI mice (Fig. 4B, P < 0.05).

**Further Characterization of the Cys521Ser KI Basal Phenotype.** Additional studies characterizing the basal phenotype of the KI were undertaken. Hematological analysis of WT and KI showed there were no differences in blood biochemistry between WT and KI (Fig. S1A). Although KI mesenteric vessels were less sensitive to NO2-OA than WT, there was no difference between genotypes in their vasodilatory responses to acetylcholine alone (Fig. 2A). NO2-OA and other free and esterified fatty acid adducts Cys521 within the EET hydrolase domain to prevent thiol modifications to be determined using an antibody to the protein of interest, in this case sEH, was undertaken. This procedure, known as the PEG-switch assay (29, 30), showed there was a basal level of reversible sEH modification in WT that was significantly increased following NO2-OA treatment (Fig. 4A, P < 0.05). In contrast, KI mice showed no such increase (Fig. 4A), a consequence of the lack of the Cys521 thiol target.

**Discussion**

A number of sEH inhibitors lower BP by limiting the hydrolysis and inactivation of vasodilatory EETs (6, 7). The sEH is also inhibited by endogenously generated and exogenously administered lipid electrophiles. These thiol-reactive lipids covalently adduct Cys521 within the EET hydrolase domain to prevent hydrolysis to their corresponding DHETs (1). Electrophilic fatty acids are likely to display selectivity in sEH adduction because of subtle, it prevents the adduction and inhibition of sEH by lipid electrophiles and manifests profound downstream physiological responses. By comparing the responses of WT and KI mice basally and in response to NO2-OA, one is positioned to establish a causal relationship between sEH inhibition by lipid electrophiles and blood pressure lowering.
Myography revealed the vasodilation of isolated mesenteric arteries in response to NO2-OA, which was impaired in KI vessels compared with WT controls. These findings are rational as the KI was specifically engineered to lack Cys521 to be resistant to such electrophiles. It is controversial as to whether lipid nitroalkenes induce vessel relaxation in biological milieu via release of NO (32, 33). Herein, NO2-OA–induced vasorelaxation was unaffected by inhibition of soluble guanylate cyclase, the major target of NO. Thus, NO2-OA does not relax vessels via cGMP-dependent mechanisms, an observation consistent with the inhibition of sEH by NO2-OA and downstream elevation in EET levels. Although the EC50 for NO2-OA–dependent mesenteric relaxation for each genotype was determined in this study, the measured values require some further consideration because the modification by the electrophile is not readily reversible. Electrophile–protein adducts are likely slowly reversible or perhaps irreversible, which makes the adductive inhibition of sEH by NO2-OA very time dependent. As a consequence, lower doses of the NO2-OA provided over a longer time may induce the same amount of protein modification as a larger amount supplied for a short time. Indeed, with longer incubation times a low concentration of the electrophile 15-deoxy-delta-12,14-prostaglandin J2, which also adducts Cys521 of sEH (1), has been shown experimentally to induce the same degree of labeling achieved acutely by a higher concentration (34). With these considerations in mind, the EC50 for NO2-OA–dependent mesenteric relaxation or sEH inhibition could substantively change, depending on the precise experimental conditions used, especially the time of exposure to the electrophile.

Next NO2-OA or vehicle was delivered systemically to each genotype using an osmotic minipump. It was not feasible to measure sEH activity in mesenteries because of the limited amount of tissue that could be harvested. Consequently, sEH activity was measured in heart tissue, where NO2-OA treatment was observed to inhibit hydrolase activity in WT but not KI. It was also noted that the sEH activity in the KI was slightly less than WT, consistent with previous studies in transfected cells.
where it was observed that the cysteine-to-serine mutation similarly reduced EET hydrolysis (1). This suggests the explanation that the Cys521 thiol may provide protonates necessary for EET hydrolysis and the addition of electrophiles to this thiol abrogates catalytic activity. Alternatively, the cysteine-to-serine mutation may induce a structural perturbation that reduces the efficiency of catalysis; an unlikely event given the mutation is subtle and conservative.

We found that the basal MAP of KI mice was ∼9 mmHg higher than littermate WTs. This might be a consequence of endogenous electrophiles basally inhibiting the WT but not the KI. Indeed, when we used a PEG-switch assay to index reversible thiol modification of sEH, there was a basal level of cysteine modification that was further elevated following treatment with NO2-OA. Moreover, both the basal and the NO2-OA-induced modification was absent in the KI. However, there is additional complexity as we found that the activity of sEH in the KI was less than the WT, which is perhaps inconsistent with hypertension in the sEH redox-null mice. We note these hydrolysis activity measurements and the PEG-switch assay, which was used to monitor the stoichiometry of modification by the electrophile, were performed with cardiac tissue, and not in resistance blood vessels, which was not technically possible. We quantified the basal EET levels in the plasma, but those measured were not different between genotypes and so they cannot account for the hypertension in the KI. However, there was a difference in the basal HETE levels in plasma from WT and KI mice. HETEs can cause vasorelaxation (35, 36), and therefore their decreased abundance in KI plasma provides an explanation for their basal hypertension compared with littermate WT. What remains undefined is the mechanism by which plasma HETE levels are lower in KI.

Ang II treatment increased BP in both genotypes, but the hypertensive response was potentiated in KI compared with WT mice. This is consistent with the presence of an endogenous lipid electrophile that inhibits WT sEH to offset the hypertensive response, whereas this mechanism cannot operate in KI as it has an exacerbated reaction to Ang II. Indeed, nitroalkenes and other electrophilic lipids may be produced endogenously in response to Ang II (37). When Ang II-induced hypertensive mice were administered NO2-OA, BP was reduced in WT but not in KI mice. The striking failure of the NO2-OA sEH to lower BP in hypertensive KI mice provides robust evidence that redox regulation of sEH by lipid electrophiles is an important regulator of BP in vivo, especially during hypertension. Indeed, the most compelling support for this concept comes from the measurement of plasma EET/DHET ratios in each genotype with or without NO2-OA treatment. NO2-OA increased the EET/DHET ratios in WT but not KI mice, consistent with the redox-null sEH variant being insensitive to modulation by lipid electrophiles. Overall, it is evident KI mice do not lower their BP in response to NO2-OA because they cannot sense and transduce the net vaso dilatory signaling actions of these electrophilic species.

Ang II treatment induced cardiac hypertrophy characteristic of the BP-elevating doses of this vasoconstrictive mediator. Consistent with NO2-OA alleviating hypertension in WT mice via increasing EET levels, this intervention also limited hypertrophy. Furthermore, as NO2-OA did not elevate EETs or lower BP in KI mice, it was ineffective in preventing cardiac hypertrophy. These observations are consistent with several studies that show pharmacological inhibition of sEH can limit cardiac hypertrophy secondary to hypertension (6, 14).

Although NO2-OA clearly reduces BP in an Ang II-induced hypertension model, as well as the associated cardiac hypertrophy, it is notable that the extent of inhibition sEH activity caused by the electrophile was rather modest. It is difficult to define how much sEH inhibition is required to lower blood BP, but what is evident is that a number of vaso dilatory EETs become elevated following this intervention in WT but not KI mice. Consequently, we can reasonably conclude that there was indeed sufficient inhibition of sEH to mediate the BP lowering. However, we are also mindful that there could be additional, yet-undefined regulatory events that also contribute to the BP lowering and anti-hypertrophic effects of NO2-OA. Another possibility to consider, although we have no evidence for such events, is that modification of Cys521 alters the product profile of the hydrodase.

Many credible mechanisms contribute to the epidemiological evidence of benefit from a Mediterranean-like diet (38, 39). The present findings support a new explanation for how cardiovascular protection can be afforded by a diet typified by consumption of unsaturated fats and vegetables abundant in nitrite and nitrate. Despite the Mediterranean diet being rich in fats that might promote cardiovascular disease, it protects against hypertension and associated risks (28). A key feature of the Mediterranean diet is the coconsumption of nitrite together with unsaturated fatty acid (e.g., from green leafy vegetables eaten with olive oil), promoting the further formation of sEH-inhibitory electrophilic fatty nitroalkenes that are also endogenously present in olives and olive oils (21). Indeed, when an unsaturated fatty acid was coadministered with sodium nitrite, using a protocol that elevates tissue nitro fatty acid levels (40), there was significant inhibition of sEH in WT but not KI mice. This mechanism for the endogenous generation of a sEH inhibitor providing cardiovascular protection is fully consistent with the actions of synthetic sEH inhibitors (41, 42). The findings of this study may provide an explanation, at least in part, for the findings of the Prevención con Dieta Mediterránea (PREDIMED) multicenter randomized trial (43), which showed a Mediterranean diet supplemented with extra virgin olive oil or nuts reduced the incidence of major cardiovascular events.

Finally, supplementation with nitrite or nitrate together and alone can also lower BP, a consequence of eventual reduction to vasodilatory NO and nitrosothiols (44, 45). It is also plausible that some of the effects of nitrite and nitrate may also be mediated by nitroalkene formation, as the host diet, intrinsic biosynthetic mechanisms, and commensal bacteria can produce an array of unsaturated fatty acids (46, 47).

Methods

More comprehensive methods are provided in SI Methods.

Generation of Cys521Ser sEH Knockin Mice. Mice constitutively expressing the sEH Cys521Ser mutation were generated on a pure C57BL/6 background by Taconic Artemis using a gene targeting vector.

Blood Biochemistry. Venous blood from WT or Cys521Ser KI mice was analyzed using a hand-held iSTAT analyzer, with ECB+ cartridges (Abbott Laboratories).

Echocardiography. Age- and weight-matched littermate WT or Cys521Ser KI mice were anesthetized and examined by echocardiography using a high-resolution Vevo 770 echocardiography system (VisualSonics).

Telemetric Blood Pressure Monitoring in Vivo. BP was assessed by remote radiotelemetry in conscious freely moving mice as described previously (48–50).

Ang II-Induced Hypertension and NO2-OA Delivery. Ang II with or without NO2-OA was delivered by osmotic minipump (model 1007D) implanted s.c.

Soluble Epoxydase Hydrolysis Activity Assay. sEH activity was measured using the 3-phenyl-oxiranyl)-acetic acid cyan- (6-methoxy-naphthalen-2-yl)-methyl ester (PHOME; Cayman Chemical) assay.

Sample Preparation for Oxylipid Profiling Analysis. This analysis was carried out as previously described in detail (51), using liquid chromatography and tandem mass spectrometry.

Assay for Quantifying the Stoichiometry of NO2-OA Addition to sEH. This is based on a modified "PEG-switch" assay that allows the stoichiometry of
Feeding Studies to Generate Endogenous Nitro Fatty Acids. Mice were gavaged daily for 5 d with conjugated linoleic acid and sodium nitrite in 200 μL PEG 400. This protocol has successfully increased endogenous nitro lipids in rodents (40), and models concentrations of key components of the Mediterranean diet. Control mice were gavaged with 200 μL PEG 400.


Statistics. Differences between groups were assessed using analysis of variance (ANOVA) where appropriate, followed by a t test. Differences were considered significant at the 95% confidence level.

ACKNOWLEDGMENTS. This work was supported by the British Heart Foundation (BHF); King’s BHF Centre of Research Excellence; Medical Research Council UK; Fondation Leducq; European Research Council; the Department of Health and the National Institute for Health Research comprehensive Biomedical Research Centre award to Guy’s & St. Thomas’ National Heart Foundation Service Trust; National Institutes of Health (NIH) Grants R01-HL058115 and R01-HL64937; National Institute on Environmental Health Sciences Grants R01-E002710 and R02-E500469; and NIH Metabolomics Center U24-DK097154.
Supporting Information

Charles et al. 10.1073/pnas.1402965111

SI Methods

Generation of Cys521Ser Soluble Epoxide Hydrolase Knockin Mice. Mice constitutively expressing the soluble epoxide hydrolase (sEH) Cys521Ser mutation were generated on a pure C57BL/6 background by Taconic Artemis. A gene-targeting vector was constructed using C57BL/6–derived genomic DNA of the Ephx2 gene from the RP23 BAC library. The Cys521Ser substitution was introduced into exon 18 using site-directed mutagenesis to change the TGT codon (National Center for Biotechnology Information (NCBI) reference sequence mouse: 13850) to TCC. A positive selection marker (Puromycin resistance, PuroR) was flanked by F3 sites and inserted into intro 16. Transfection of germ-line–competent C57BL/6N Tac ES cells with linearized and purified targeting vector DNA was then carried out. G418–mediated enrichment of ES cell clones that had integrated the targeting vector into their genome and Southern analysis of genomic DNA from G418–resistant ES cells with an Ephx2 locus–specific probe yielded a number of candidate clones. Candidate clones were tested for correct homologous recombination at the target locus and the absence of additional integrations of the targeting vector by Southern analysis with targeting-vector–specific (internal) and target-locus–specific (external) probes in combination with multiple restriction digestions. Injection of cells from one correctly targeted ES cell clone into wild-type (WT) blastocysts yielded male mice with 50–100% chimerism, as judged from coat color. Chimeric males with a high contribution of targeted ES cells were directly bred with a transgenic mouse line [C57BL/6-Tg(CAG-Flpe)2 Aret] ubiquitously expressing Fsp recombinase under the control of the chicken β-actin promoter and a hCMV immediate early enhancer for germ-line transmission of the targeted sEH knockin allele and in vivo deletion of the flippase recognition target-flanked selection marker. The presence of the C43S point mutation was confirmed in both ES cells and mice heterozygous for the targeted sEH allele by sequencing of genomic DNA. Mice were maintained as stated in the Principles of Laboratory Animal Care published by the National Institutes of Health (NIH Publication Number 85–23). Experiments were approved by the King’s College London Animal Welfare and Ethical Review Body. The sEH Cys521Ser mice were characterized by comparing them to their WT littermate controls as reported in Figs. 1–4 of this study. Additional characterization data are provided in Fig. S1 A–C.

Blood Biochemistry. Venous blood from WT or Cys521Ser KI mice were analyzed using a hand-held iSTAT analyzer, with EC8° cartridges (Abbott Laboratories).

Myography. Vascular rings were isolated from the mesenteric (second order) arteries. The rings were mounted in a tension myograph (Danish Myo Technology), stretched to the optimal pretension conditions (using a Danish Myo Technology Normalization Module), bathed in Krebs solution maintained at 37 °C and gassed with 95% CO2:5% O2 (vol:vol). During the vessel “wake up” phase, if vessels did not generate greater than 1 mN of force, they were rejected and the myograph channel was switched off. No vessels were rejected during subsequent analyses of the responses. Vasotone measurements of mesenteric vessels were made by determining the responses of U46619-contracted (0.1 μM; Sigma) vessels to nitro-oleic acid (NO2–OA) (0–10 μM). In some experiments, mesenteric vessels were incubated in 20 μM 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; Sigma) for 30 min before U46619 contraction and dose–response to NO2–OA. In some studies acetylcholine (dose–response; Sigma), l-N2O–nitroarginine methyl ester (l-NAME) (300 μM; Sigma) and indomethacin (10 μM; Sigma) was used. Tension experiments were carried out using at least three vessels per treatment intervention derived from at least three different WT or knockin (KI) mice.

Echocardiography. Age- and weight-matched littermate WT or Cys521Ser KI mice (four per group) were anesthetized and examined by echocardiography using a high-resolution Reson 770 echocardiography system (VisualSonics) with a RMV-707B transducer running at 30 MHz. High-resolution, 2D brightness mode and motion-mode images at the level of the papillary muscles were obtained. Wall thickness and ventricular dimensions were measured and then left ventricular mass, ejection fraction, stroke volume, and cardiac output were calculated with Vevo Software (VisualSonics).

Telemetric Blood Pressure Monitoring in Vivo. Blood pressure (BP) was assessed by remote radiotelemetry in conscious freely moving mice. Briefly, mice were anesthetized with 2% isoflurane (Centaur Services) in 1 L of oxygen per minute with pre- and postoperative analgesia (buprenorphine, 0.1 mg per kg of body weight; Abbot Laboratories). A radiotelemetry probe catheter (TA11PA-C10, outside diameter of 0.4 mm; Data Science International) was implanted into the aortic arch of each mouse through the left carotid artery. After 1 wk of recovery, mice housed individually in cages were placed above the telemetric receivers with an output to a computer. Blood pressure was recorded by scheduled sampling for 10 s every 5 min (Dataquest LabPRO Acquisition system version 3.01; Data Sciences International). Baseline measurements were initiated after 1 wk postsurgery recovery and subsequent NO2–OA, angiotensin (Ang) II, and saline delivery (below). A total of 7–12 WT or KI mice were studied per group to produce the average blood pressure data. Ang II–Induced Hypertension and NO2–OA Delivery. After baseline recordings (3 d) mice were again anesthetized and subjected to s.c. implantation of osmotic minipumps (model 1002; Alzet) for delivery of Ang II (Sigma) at an infusion rate of 1 mg/kg/day. After 3 d, a second osmotic minipump (model 1007D) containing either NO2–OA, angiotensin (Ang) II, and saline delivery (below). A total of 7–12 WT or KI mice were studied per group to produce the average blood pressure data. In some experiments, mice had only one osmotic minipump implanted with NO2–OA or saline.

Soluble Epoxide Hydrolase Activity Assay. Mouse hearts from Welmedemetered animals were rapidly isolated and frozen in liquid N2 at the end of the BP monitoring protocol. Hearts were powdered under and stored in liquid nitrogen until ready for analysis. They were homogenized (1 mL of buffer per 100 mg of cardiac tissue) on ice in 100 mM Tris-HCl, pH 7.4 using a Polytron tissue grinder. Cytosolic fractions were prepared from the hearts by centrifugation at 25,000 × g for 5 min at 4 °C. A total of 20 μL of the cytosolic fraction was then used for the activity assay, adding it to 175 μL of 25 mM Tris-HCl, pH 7.4. After equilibration at room temperature, the reaction was initiated by the addition of 5 μL of 10 μM (3-phenyl-oxiranyl)-acetic acid cyano–(6-methoxy-naphthalen-2-yl)-methyl ester (PHOME; Cayman) dissolved in DMSO. The reaction mixture was left for 15 min, after which the fluorescence was monitored at 330/465 nm. In an additional reaction mixture, an sEH inhibitor [5 μL of 10-μM

Charles et al. www.pnas.org/cgi/content/short/1402965111
12-(3-adamantan-1-yl-ureido)dodecanioic acid; Cayman] was added to ascertain the baseline reading for sEH activity for each sample.

Sample Preparation for Oxylipid Profiling Analysis. Plasma samples were spiked with 10 μL 500 nM internal standard I [d4-6-keto-prostaglandin F1α, d4-prostaglandin E2, d4-thromboxane2, d4-leukotriene B4, d11-14,15-dihydroxy-eicosatrienoic acid, d6-20-hydroxy-eicosatetraenoic acid (HETE), d4-9-hydroxy-octadecadienoic acid, d8-12-HETE, d8-5-HETE, d11-11(12)-epoxy-eicosatrienoic acid, d4-9(10)-epoxy-octadecenoic acid, d8-AA] and then were extracted by solid phase extraction using Oasis hydrophilic-lipophilic-balanced (HLB) cartridges (3 cc 60 mg; Waters). The HLB cartridges were first washed with 2 mL ethyl acetate, 2 mL methanol twice, and 2 mL 95:5 vol/vol water/methanol with 0.1% acetic acid. The 6-mL plasma samples were then loaded onto the cartridges with 3-mL samples each time. The samples were then washed with 6 mL 95:5 vol/vol water/methanol with 0.1% acetic acid and dried for 20 min with low vacuum. The target analytes were then eluted with 0.5 mL methanol followed by 2 mL of ethyl acetate into the tubes with 2 μL 30% glycerol in methanol as the trap solution. The volatile solvents were evaporated by using vacuum centrifugation (SpeedVac) until 2 μL of trap solution remained in the tube. The residues were dissolved in 50 μL of methanol containing 200 nM internal standard II (1-cyclohexyl-dodecanoic acid urea, CUDA). The samples were mixed with a vortex mixer for 2 min, centrifuged at 14,000 × g for 5 min, and then transferred to autosampler vials with 150 μL for liquid chromatography tandem MS (LC/MS/MS) analysis. LC/MS/MS analysis of oxylipids was performed using an Agilent 1200 SL liquid chromatography series (Agilent) with an Agilent Eclipse Plus C18 2.1 × 150 mm, 1.8-μm column for the oxylipins separation. The mobile phase A was water with 0.1% acetic acid, whereas the mobile phase B was composed of acetonitrile/methanol (80/15, vol/vol) and 0.1% acetic acid. Gradient elution was performed at a flow rate of 250 μL/min. The injection volume was 10 μL and the samples were kept at 4 °C in the autosampler. Analytes were detected by negative multiple reaction monitoring mode using a 4000 QTrap tandem mass spectrometer (Applied Biosystems) equipped with an electrospray ionization source (Turbo V). Calibration curves were generated by 10-μL injections of seven standards containing each analyte, internal standard I, and internal standard II for quantification purposes.

Assay for Quantifying the Stoichiometry of NO2-OA Adduction to sEH. This is based on a modified “PEG-switch” assay that allows the stoichiometry of reversible thiol oxidations to be determined using a Western blotting-based approach and an antibody to the protein of interest, namely sEH in these studies. The method, adapted to use β-mercaptoethanol (β-Me), as it allows reductive labeling of proteins that adduct NO2-OA. Briefly, hearts from mice that had been subjected to 7 d of saline or NO2-OA treatment from a minipump were rapidly isolated and frozen in liquid nitrogen. Tissue samples were powdered under and stored in liquid nitrogen until subsequent analysis, when they were homogenized (1 mL of buffer per 100 mg of cardiac tissue) on ice in 100 mM Tris·HCl, pH 7.4, 100 mM maleimide, and 1% SDS using a Polytorn tissue grinder. The samples were heated at 37 °C for 60 min to reverse NO2-OA adducts. The samples were desalted with a spin column (Pierce) and then 500 mM β-Me was added. The samples were heated at 37 °C for 60 min to reverse NO2-OA adducts. The samples were desalted with a spin column again and 10 mM PEG-maleimide (Sigma) and 0.5% SDS were added to the sample, which was left rotating for 2 h at room temperature. A 2× SDS sample buffer [100 mM Tris·HCl, pH 6.8, 4% SDS (vol/vol), 20% glycerol (vol/vol), and 0.01% bromophenol blue] containing 100 mM maleimide was added to each sample. The samples were then resolved on a standard SDS/PAGE gel, Western blotted, and probed with an antibody for sEH (H-215, sEH antibody; Santa Cruz Biotechnology). GelPro Analyzer 3.1 was used to quantify the proportion of PEG-modified sEH to that of the reduced sEH.

Feeding Studies to Generate Endogenous Nitro Fatty Acids. Mice were gavaged daily for 5 d with conjugated linoleic acid (CLA, 10 mg/kg) and sodium nitrite (20 mg/kg) in 200 μL PEG 400. This protocol models concentrations of key components of the Mediterranean diet. Animals were killed 2 h after the last dose and tissues were rapidly isolated and frozen in liquid nitrogen. Control mice were gavaged with 200 μL PEG 400.
Fig. S1. Comparison of basal phenotype of WT and sEH KI mice. (A) Hematological analysis of WT and KI showed there were no differences in terms of WT and KI blood biochemical indices. (B) Myograph analysis showed there was no difference between either genotype in their vasodilatory responses to acetylcholine or acetylcholine in the presence of L-N^6-nitroarginine methyl ester (L-NAME) and indomethacin. (C) Echocardiographic analysis of cardiac function showed there were no differences in basal heart function parameters between WT and KI mice. LV mass, left ventricular mass; SV, stroke volume; EF, ejection fraction; FS, fractional shortening; CO, cardiac output; IVS, interventricular septum thickness; LVPW, left ventricular posterior wall thickness; LVAW, left ventricular anterior wall thickness; LVID, left ventricular internal dimension.